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Abstract
Tuberculosis (TB) is still an ongoing public health concern in African, Asian and South American
countries, where it still has a strong prevalence, resulting in a heavy economic, social and human
burden.  In  2011,  the  World Health Organization (WHO) has  reported  an  estimated  1.4 million
deaths  due to TB, a disease caused by the infection of  Mycobacterium tuberculosis (MTb). There
have been determined efforts to fight this disease, and the search for new antitubercular drugs plays
a crucial role. In spite of these efforts, the most recent drug in the market dates back 50 years, and
so new delivery strategies that improve the efficacy of existing treatments may become important in
this fight.
The goal of this work was to develop a nanocarrier system for the delivery of antitubercular
drugs. The chosen nanocarriers were lipid nanoparticles, more specifically nanostructured lipid con-
jugates  (NLCs). These particles were loaded with two anti-tubercular drugs: rifampicin (RIF) and
rifabutin (RFB). Since the lung is the primary site of infection in TB, the proposed route of adminis-
tration for this strategy is the pulmonary route. Once inhaled, the particles should be able to travel
to the pulmonary alveoli and reach the alveolar macrophages (AMs). Produced particles thus must
have an appropriate size, otherwise they will be trapped in the upper airways or leave the lung on
exhaling. Also, it is known that AMs have specific receptors that bind to sugars. Surface modifica-
tion by mannose coating was performed to take advantage of these receptors and improve cellular
uptake by AMs.
The  developed particles were characterized in  terms of size,  zeta  and morphology.  Results
showed particles with size and morphology suitable to reach the pulmonary alveoli, and loading
efficiency for both drugs was above 80%. The success of mannose coating was confirmed by FTIR
analysis.  Cytotoxicity of the formulation was evaluated by MTT assay with three different cell
lines.
Although more studies are definitely needed, the results from the present work pose a strong
argument for NLCs as a promising strategy for the pulmonary delivery of antitubercular drugs.
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Resumo
A tuberculose (TB) apresenta-se ainda como um problema de saúde pública considerável em países
Africanos, Asiáticos e Sul Americanos, onde ainda tem uma elevada prevalência, resultando num
pesado fardo económico, social e humano. Em 2011, a Organização Mundial de Saúde estimou que
a TB terá sido responsável, em todo o mundo, por 1.4 milhões de mortes. A TB é uma doença cau-
sada pela infeção por  Mycobacterium tuberculosis.  Inúmeros esforços têm sido concentrados no
combate a esta doença, e a pesquisa por novos fármacos tem, aqui, um papel preponderante. No
entanto, e apesar destes esforços, o mais recente fármaco para o combate à TB tem já 50 anos.
Novas estratégias de transporte e libertação de fármacos, que melhorem a eficácia dos tratamentos
já existentes, poderão tornar-se importantes nesta luta.
O objectivo deste trabalho foi desenvolver um sistema de nanopartículas para o transporte e
libertação de fármacos de combate à TB. As nanopartículas escolhidas foram nanopartículas lipídi-
cas, mais especificamente partículas lipídicas nanoestruturadas (NLC). Nestas foram introduzidos
dois fármacos: rifampicina (RIF) e rifabutina (RFB). Dado que os pulmões são o principal foco de
infecção por TB, a via de administração proposta é a inalatória. Uma vez inaladas, as NLC deverão
depositar-se nos alvéolos pulmonares, onde se encontram os macrófagos alveolares (AMs). As par-
tículas produzidas deverão, portanto, ter um tamanho apropriado a este objectivo. É também conhe-
cido  que  os  AMs têm receptores  de açúcares  específicos.  A superfície  das  partículas  foi  então
modificada para expor moléculas de manose, com o ojbectivo de aumentar a
As nanopartículas desenvolvidas foram caracterizadas em termos de tamanho, potencial zeta e
morfologia. Os resultados revelaram  partículas com tamanho e morfologia adequados para atingir
os alvéolos pulmonares. A taxa de incorporação para ambos os fármacos foi acima de 80%. A modi-
ficação da superfície com manose foi confirmada por análise FTIR. A citotoxicidade foi avaliada
por ensaios de MTT, com três linhas celulares.
Mais estudos são definitivamente necessários, mas os resultados do presente trabalho apresen-
tam um forte argumento a favor da utilização de NLC como uma promissora estratégia para a admi-
nistração pulmonar de fármacos no combate à TB.
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1 Introduction
1.1 Motivation
Tuberculosis  (TB)  is still far from being a health concern of the past. Although less frequent in
European countries and North America, it has a strong prevalence in Africa, Asia and South Amer-
ica. In 2011, the World Health Organization  (WHO) reported an estimated 8.7 million new cases
and 1.4 million deaths from TB, thus making it the second leading cause of death by infectious dis-
eases in the world. To address this heavy public health burden, in 2006 the WHO lauched the Stop
TB Strategy. The goals of this strategy are, for 2015, to reduce prevalence of and deaths due to TB
by 50% compared with a baseline of 1990, and for 2050, to eliminate TB as a public health prob-
lem [1].
The search for new anti-TB drugs is, of course, of key importance in this fight, but notwith-
standing this search, new drug delivery strategies may also play an important role. Alternative deliv-
ery systems,  such as  nanocarriers  for  anti-TB drugs,  may reduce  administration  frequency and
shorten periods of treatment, hence improving patient compliance and efficacy of treatment, and
reduce drug related toxicity [2].
This constituted the major motivation factor behind this work. It's main goal was the develop-
ment of a new delivery strategy for the treatment of TB, through the use of lipid nanoparticles as
carriers for  two rifamycins (i.e.  rifampicin and rifabutin),  commonly used as  anti-TB drugs. The
aim of this project was to produce a nanosystem for pulmonary administration, featuring both pass-
ive and active targeting strategies, in order to improve drug uptake by alveolar macrophages.
1.2 Characterization of TB
TB is a disease caused by the infection of Mycobacterium tuberculosis (MTb). It can affect practic-
ally all organs of the human body, but the lung (pulmonary TB) is of particular high incidence. This
is to be expected, since the infection starts with the inhalation of bacilli of MTb during breathing,
leading the bacteria directly to the lung. Due to their size, the bacilli are able to reach the pulmonary
alveoli, where they are phagocyted by the alveolar macrophages (AMs) [3] (Figure 1).
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Inside the AMs, the bacilli reside in a membrane-bound vacuole, and for this reason some are able
to avoid fusion with lysosomes and posterior digestion [4], ending up co-existing with the AMs [5].
They multiply  and  eventually  escape  the  lung  through the  bloodstream and lymphatic  system,
spreading to other organs of the body, resulting in the extra-pulmonary TB [6](Figure 2). Moreover,
MTb may exist within a granulomas consisting of macrophages and giant cells, T cells, B cells, and
fibroblasts, and these granulomas can prevail not only in the lung, but in other organs as well. In lat-
ent infections, the state of the bacteria within the granuloma is unknown. The estimates are that one
third of  the world's  population  is  infected  with  the  organism,  although usually the infection is
present in its dormant state [7].
Some symptoms may be associated with pulmonary TB and extra pulmonary TB, and they
could be of help when diagnosing the disease. In pulmonary TB, symptoms include cough, produc-
tion of sputum in later stages (due to inflammation and tissue necrosis), hemoptysis (only in rare
cases),  pleuritic  pain,  dyspnea (unusual,  unless there is  extensive disease),  and may also cause
severe respiratory failure. X-ray of the lung and examination of sputum is often used to confirm
pulmonary TB. Extra pulmonary TB has a wider range of symptoms, depending on which organ is
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affected, and in many cases infection produces sys-
temic effects, rather than local ones. Moreover, these
effects  are  many  times  associated  with  other  ail-
ments, such as human immunodeficiency virus (HIV)
infection, diabetes mellitus, and neoplastic diseases,
which  considerably  delays  diagnosis  and  increases
misdiagnoses,  specially  with  patients  co-infected
with HIV [8].
1.3 Traditional chemotherapy
Treatment for TB almost always involves a cocktail
of drugs administrated through long periods of time,
which contributes to patient non-compliance, result-
ing in multi  drug resistant  (MDR),  extremely drug
resistant (XDR)  [1], and even totally drug resistant
strains of TB, which are considerably harder to treat
[9] (Figure 3). Also, progress on new drug therapies
has been developing slowly, and the most recent of anti-TB drugs currently in use dates back 50
years. Sarkar et al., in their review of the present TB chemotherapy available and of new and emer-
ging drugs, stressed how essential further research in a new drug target is to fight MDR and XDR
TB [2]. 
Currently available chemotherapy includes first-line drugs, such as isoniazid, pyrazinamide,
rifampicin,  and  ethambutol,  and  second-line  drugs,  such  as  para-aminosalicylic  acid,
ciprofloxacin/ofloxacin,  clofazimine,  cycloserine,  ethionamide,  rifabutin,  streptomycin,  and thio-
acetazone  [10]. These second-line drugs are only used when treatment with first-line drugs fails.
They are less effective, more toxic, and unavailable in many countries due to high costs [11]. The
two drugs used in the present work were rifampicin (RIF) and rifabutin (RFB). They belong to the
family of rifamycin antibiotics, which are among the most potent anti-tuberculosis agents known.
They possess a unique ansa structure consisting of an aromatic nucleus linked on both sides by an
aliphatic bridge [12]. RIF is a red crystalline powder. It exhibits a half life between 2.3 and 5 hours
on initiation of therapy, but this value decreases to between 2 and 3 hours after repeated treatment.
Rifabutin (RFB) is a violet crystalline powder. It has a longest half life, between 32 and 67 hours,
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but it also shows increased toxicity, and adverse effects include rash, gastrointestinal disturbance,
neutropenia, and occasional uveitis [10].
There are several new drug candidates currently in research and in clinical trials, and several exist-
ing drugs are in a state of re-evaluation [9]. In December 2012, the FDA granted an accelerated
approval of a new drug, bedaquiline, but only as part of a combination therapy to treat adults with
MDR TB when other alternatives are not available [13]. However, bedaquiline has not yet gone
through a phase III trial, and several accounts of heart failure have been reported, which may result
in bedaquiline being removed from the market. This illustrates how important it is to find new
strategies to fight this disease.
1.4 Outline of the dissertation
The present dissertation is divided in five chapters.
Chapter 1, the present chapter, constitutes a brief introduction to the theme and the main goals
of the dissertation. 
Chapter 2 presents some scientific considerations of TB and it's current treatment options, and
it ends with a state of the art regarding nanosystems as carriers for anti-TB drugs. This state of the
art, with appropriate modifications, is intended to be submitted for publication as a review article.
In Chapter 3, the materials and methods used in the present work are presented and explained.
Results from the experimental work are shown and discussed in Chapter 4.
Finally, Chapter 5 constitutes an overall reflection on the goals and achievements of this work.
It also tries to outline possible paths for future work.
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2 Nanosystems for the pulmonary 
delivery of anti-tuberculosis drugs
Since the lung is the most important point of access in the case of infection by MTb  [14], [15],
exploiting the inhalatory route for drug delivery becomes an exciting hypothesis to fight the dis-
ease [16]–[18]. Indeed, the lung is the ideal target site for anti-TB drug delivery, and could provide
a delivery portal  requiring smaller doses for efficacy, exhibiting reduced toxicity and fewer side
effects  [3].  Also,  the  respiratory system behaves  as  an  “aerosol  filter”,  a  property that  can  be
exploited to target particles having specific attributes to the lung [15], and since the lung mucosa
has a large surface from which drugs may be systemically absorbed into the bloodstream, escaping
the first-pass metabolism [14], enhancing overall bioavailability. This makes pulmonary delivery of
drugs an interesting approach for the treatment of pulmonary infections. Adding to this,  as was
described  in  section  1.2, pathogenic  TB  bacilli  establish  infection  mainly  in  alveolar  macro-
phages [16]. In this regard, it would be of interest not only to deliver the drugs to the lung, but also
to achieve phagocitosys by AMs.
2.1 Lung deposition
To achieve lung deposition, particle size is the
most  important  characteristic  to  take  into
account [19].  Figure  4 illustrates  the  influence  of
particle size in lung deposition. Particles with dia-
meters  greater  than  5 μm deposit  primarily  in  the
mouth and upper airways, while particles with dia-
meters ranging from 1-5 μm are the most efficient to
reach  the  deep  lung.  With  particles  bellow  1µm,
mechanisms  such  as  diffusion  and  sedimentation
become important in reaching the pulmonary alve-
oli, and such could be exploited to optimize pulmon-
ary delivery strategies [20], [21]. Particle size is also
5
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an important characteristic in passive targeting of macrophages, since they affect the success of
internalization within these cells. In this regard, particles with diameters of about 500 nm have been
reported as ideal to undergo phagocytosis by AMs [18].
2.2 Pulmonary administration
Pulmonary administration of drugs must be done using a suitable device. Currently, there are three
main delivery devices used for this purpose: nebulisers, pressurized metered-dose inhalers (MDIs),
and dry powder  inhalers  (DPIs).  They behave differently and  are  used  with  different  kinds  of
particles [22]. MDIs and DPIs are popular choices for the treatment of pulmonary chronic diseases.
DPIs are particularly popular, since they are propellant-free, portable, easy to operate and low-cost
devices. Unfortunately, dry powders tend to result in particle aggregation, increasing the aerody-
namic diameter and lowering the fraction that is respirable, compromising the technique, and ren-
dering them unable to reach the deep lung regions where alveolar macrophages lie. Nebulisers may
prove to be a better choice, since they can generally produce liquid droplets which are smaller, and
thereby provide the opportunity for a larger proportion of the drug to reach the deep lung regions
[17].
Although promising and vastly researched, these delivery strategies face obstacles difficult to
overcome. With the particular case of anti-TB drugs, so far not one formulation has reach the mar-
ket [14]. These difficulties have been reported throughout the scientific literature, and include: the
use of safe and accepted excipients, developing scalable processes, developing droplets with proper
particle  size and morphology for lung deposition,  and achieving satisfactory drug loading  [14].
Also, usable strategies must be able to account for different lung structures, breathing patterns, and
changes  in  the airway morphology by the pathogenic agent  [15].  They must  achieve access to
poorly-aerated areas of the lung and extracellular bacteria in well-aerated lung tissue, overcoming
induction of resistance due to depletion of intracellular drug concentrations, and surpassing limita-
tions due to possible innate responses of the host  [23]. The use of nanosystems may be of key
interest in overcoming the above-mentioned obstacles.
2.3 Active targeting of alveolar macrophages
As stated before, by fine tunning the size of the carrier system, we can enhance phagocitosys by
AMs, a desirable event in the case of pulmonary TB. To this passive targeting strategy, there are act-
ive targeting strategies that can be used to improve treatment efficacy. In active targeting strategies,
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the constitution and/or structure of the nanosystems is modified, so that certain ligands are present
at their surface, changing the way the system interacts with surfaces and cells.
Macrophages exhibit a number of receptors that can be exploited by nanocarriers with appro-
priate ligands. Sugars, such as mannose [24] and lactose [25], are among the most commonly used
for this purpose, since these receptors are highly expressed in macrophages.  Other ligands com-
monly  used  for  macrophage  targeting  include  maleylated  bovine  serum  albumin  (MBSA),
O - steroyl amylopectin (O-SAP), tetrapeptid tuftsin [26], and anionic lipids,  such as dicetylphos-
phate (DCP).
2.4 State of the art
Nanotechnology is an area of science regarding the design and study of structures, called nano-
particles (NPs), in which at least one of the dimensions is measured at the nanoscale range (1 nm –
1000 nm). NPs display unique physical and chemical properties that significantly change with their
size. In some cases, particles with dimensions greater than 1µm are considered nanoparticles, since
they share some, or even most, of these physical and chemical characteristics.
NPs can be used for medical purposes, namely as nanocarriers for therapeutic and diagnostic
agents by means of encapsulation, covalent attachment, or surface adsorption of these agents [27].
The use of NPs in strategies for pulmonary drug delivery is a promising area of research for several
reasons. First, the size of these particles can be fine tuned to reach different areas of the lung, allow-
ing for successful passive targeting strategies. Second, their surface can be modified and ligands
attached to actively target bodies of interest, such as AMs [20]. Third, studies have demonstrated
that pulmonary delivery of nanosuspensions favor higher lung tissue concentrations and markedly
raise the lung to serum ratio of drugs, compared with other routes of administration [28]. This could
improve bioavailability, reduce side effects, drug toxicity and dosing frequency, which ultimately
leads to the increase of patient compliance and better efficacy of treatment [29].
The most frequent approach in these strategies is the use of neutral nanoparticles as carriers for
the drug. Common carriers to achieve pulmonary delivery are lipid NPs, polymeric NPs and lipos-
somes. Other formulations currently in research include the production of drug nanocrystals, aero-
sols with magnetic nanoparticles,  nanoparticles with effervescent activity,  and gold NPs for the
study of internalization of NPs by AMs (Figure 5).
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2.4.1 Polymeric based NPs
Natural and synthetic polymers are used to produce polymeric NPs as nanocarriers for drug deliv-
ery [30]. Polymeric NPs are among the most widely researched systems for drug delivery in gen-
eral,  and  many  reports  focus  on  pulmonary  delivery  in  particular.  Nanocarriers  consisting  of
poly(lactide-co-glycolide) acid (PLGA), alginate, gelatine, and chitosan are widely found in the lit-
erature. These delivery systems fulfill most requirements placed for pulmonary delivery, such as
sufficient association of the therapeutic agent with the carrier particles, targeting of specific sites or
cell populations in the lung, protection of the therapeutic agent against degradation, release of the
therapeutic agent at a therapeutically optimal rate, ability to be transferred into an aerosol, low tox-
icity,  and stability against  forces  generated during aerosolization [31].  They are also interesting
materials for the engineering of biodegradable nanocarriers [32]. Many reports on pulmonary deliv-
ery using polymeric based nanocarriers have been proposed for a variety of therapeutic strategies,
from gene delivery [31], [33]–[35] to more conventional drug delivery [36], [37].
Drug delivery formulations with anti-TB drugs have already been used with these nanocarriers.
Jain et al. compared four different NP formulations for ciprofloxacin delivery, three of them being
polimeric NPs [38]. The authors incorporated the drug within albumin, gelatin and chitosan NPs
and studied their drug release profiles. Of the three polymers, chitosan and albumin NPs proved to
be more capable of drug incorporation and sustained release.
Other studies usually focus on one type of nanosystem, although with multiple drugs. Alginate
nanoparticles have been studied by Zahoor et al. for the incorporation of rifampicin, isonizid and
 8
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pyrazinamide [39]. The mentioned particles had aerodynamic diameters in the breatheble range, and
presented high drug encapsulation efficiencies for each of the three drugs. Bioavailability of all for-
mulations was studied, and these formulations showed better results than the administration of free
drugs. Saraogi et al. used gelatin NPs for the delivery of isoniazid, and they associated them with
active targeting by the inclusion of mannose in the formulations [40]. Their study included drug
release,  macrophage  uptake,  biodistribution  and  antitubercular  activity  studies.  They  obtained
entrapment efficiencies of around 50%, and reported higher accumulation of isoniazid in the lungs
when using mannosylated NPs, rendering them suitable for pulmonary delivery of anti-TB drugs.
Abdulla and coworkers used two different molecular weights of poly-(ethylene oxide)-block-
distearoyl phosphatidyl-ethanolamine (mPEG2000–DSPE and mPEG5000–DSPE) polymers to pro-
duce nanocarriers for pulmonary delivery of rifampicin [41]. They reported high drug loading and
entrapment efficiencies, and noticed that these values were influenced by drug:polymer ratio, but
not by mPEG–DSPE molecular weight. Particle size and aerodynamic characterization showed that
prepared formulations are suitable for lung deposition through inhalation.
Chitosan has some important reported properties to act as an inert carrier, such as biocompatib-
ility, low toxicity and biodegradability, it is mucoadhesive and has the capacity of promoting macro-
molecules permeation through well-organized epithelia [42]. Moreover, it has recently been shown
that cross-linked chitosan NPs can be used with pressurized metered dose inhalers (pMDIs) [43].
This recent study also showed that this approach could be used for local therapy of lung diseases,
such as TB.  Pourshahab  et al.  used chitosan NPs as nanocarriers  for isoniazid,  and obtained a
release profile with an initial drug release burst, followed by slow and sustained release in the fol -
lowing 6 days [44].
PLGA NPs are extremely common in nanosystems, and have been used to encapsulate some
anti-TB drugs. Sung  et al. demonstrated that PLGA NPs loaded with rifampicin could be formu-
lated, resulting in particles with aerosol properties suitable for lung delivery [45]. They have per-
formed  in  vivo studies,  and  found  evidence  of  delayed  release  of  the  drug.  The  presence  of
rifampicin in the lung was detected up to eight hours after the delivery. Jain et al. reported enhanced
results when using PLGA NPs conjugated with lactose [25]. The conjugated particles resulted in
greater average size and drug payload, slower drug release, and enhanced uptake in lung tissue,
mainly due to  active targeting of AMs with lactose.  Pandey,  Sharma and coworkers have used
PLGA NPs for the incorporation of rifampicin, isoniazid and pyrazinamide, and administrated them
through oral and pulmonary routes [46], [47]. They reported the presence of rifampicin in plasma
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for 4-6 days, and of isoniazid and pyrazinamide for 8-9 days. Later, they reported that five doses of
nebulized anti-TB PLGA NPs achieved the equivalent therapeutic benefits of 46 daily doses of
orally administered free drug [46]. In 2004, the same authors, in further studies, coated similar NPs
with wheat germ agglutinin, and reported an increased period during which all drugs were detect-
able in plasma, namely 6-7 days for rifampicin and 13-14 days for isoniazid and pyrazinamide [47].
Incorporation of hydrophilic drugs in polymeric nanosystems proves to be challenging. Cheow
and Hadinoto modified PLGA preparation methods to achieve higher encapsulation efficiencies of
water soluble antibiotics, using levofloxacin as the model drug [48]. They have modified the single
emulsification-solvent-evaporation method by including lecithin into the aqueous phase, and the
double emulsification-solvent-evaporation method by increasing the water-miscibility level of the
oil phase, and succeeded in enhancing encapsulation efficiency in both cases, with no loss regarding
drug release profiles and antibacterial activity after spray drying. In other instance, they developed
lipid-polymer hybrid NPs to incorporate levofloxacin, ciprofloxacin, and ofloxacin [49]. After ini-
tial burst release, hybrid NPs showed a slower drug release than its non-hybrid counterparts. Table 1
summarizes the above mentioned studies on polymeric NPs.
Table 1: Polymeric NPs for incorporation of anti-TB drugs
Particle(s) Drug(s) Loading
efficiency
Size Ligand  In vitro/in vivo results Ref.
Alginate Rifampicin, 
Isonizid and 
Pyrazinamide
70 – 90% ~236 nm N/A Increase in bioavailability was 
confirmed.
All drugs were detected: in plasma,
up to 14 days; in tissues, up to 15 
days. 
[39]
PLGA Rifampicin 38-42% 121-184 nm Lactose As compared to unconjugated NPs, 
lactose conjugated NPs showed 
greater average size and drug 
payload, slower drug release, and 
enhanced uptake in lung tissue.
[25]
PLGA PNAPs Rifampicin N/A NPs: ~195 nm 
PNAP: ~4µm
N/A In vitro release studies: 80% 
of drug content almost immediately
released, with the remainder 
available for release over a period 
beyond eight hours .
Rifampicin concentrations in the 
lung remained elevated for 
all PNAP formulations 
[45]
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Table 1: Polymeric NPs for incorporation of anti-TB drugs
Particle(s) Drug(s) Loading
efficiency
Size Ligand  In vitro/in vivo results Ref.
PLGA
(modified 
methods)
Levofloxacin 4 – 23 % 
(depending on 
the modifica-
tion)
110 – 700 nm
(depending on 
the 
modification)
N/A Encapsulation efficiency was 
increased by employing modified 
methods for PLGA preparation, and
drug release was maintained or 
improved.
Antibacterial activity was 
maintained after spray drying.
[48]
PLGA Rifampicin, 
Isoniazid and 
Pyrazinamide
54% for 
rifampicin, 64%
for isoniazid 
and 67% for 
pyrazinamide 
180 – 290 nm 
for uncoated 
NPs.
350 – 400 nm 
for coated NPs.
Wheat germ 
agglutinin 
Presence in plasma for uncoated 
PLG-NPs: 4-6 days for rifampicin 
and 8-9 days for isoniazid and 
pyrazinamide.
Presence in plasma for coated 
PLG-NPs: 6 -7 days for rifampicin 
and 13 -14 days for isoniazid and 
pyrazinamide.
[47]
PLGA Rifampicin, 
Isoniazid and 
Pyrazinamide
57% for 
rifampicin, 66%
for isoniazid 
and 68% for 
pyrazinamide. 
186 – 290 nm N/A Presence in plasma: up to 6 days 
for rifampicin, and up to 8 days for 
isoniazid and pyrazinamide.
All three drugs were present at 
therapeutic concentrations in the 
lungs till day 11.
[46]
MPEG2000
and mPEG5000
DSPE
Rifampicin 84 – 104% mPEG2000:
226 – 396 nm
 mPEG5000:
163 – 233 nm. 
N/A In vitro results showed prolonged 
drug release over 3 days.
[41]
Chitosan DNA plasmid
encoding 
eight HLA-
A*0201-
restricted T-
cell epitopes 
from MTb
Over 99% ~376 nm N/A Pulmonary delivery of chitosan-
DNA nanoparticles resulted in 
higher IFN-γ secretion in 
comparison to both pulmonary 
DNA solution and intramuscular 
injection. The chitosan 
nanoparticles were shown to 
protect plasmid DNA from DNase I
degradation
[50]
Chitosan Isoniazid 17% 241 – 449nm
(depending on 
chitosan/TTP 
ratio)
N/A In vitro studies showed an initial 
burst release of isoniazid up to 4 h, 
followed by a more gradual and 
sustained release phase for the 
following 6 days. 
[44]
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Table 1: Polymeric NPs for incorporation of anti-TB drugs
Particle(s) Drug(s) Loading
efficiency
Size Ligand  In vitro/in vivo results Ref.
Gelatin Isoniazid 55% (uncoated) 
and 43% 
(coated)
234 nm 
(uncoated) and 
343 nm (coated)
Mannose In vitro studies show an initial 
burst, followed by a slower 
sustained release over a period of 
120h.
Macrophages uptake was found to 
be higher with coated NPs than 
with uncoated ones. 
Biodistribution studies revealed a 
higher drug content of INH in the 
liver, spleen, plasma and lung, for 
coated and uncoated NPs.
[40]
PC/TPGS lipid 
-polymer hybrid 
NPs
Levfloxacin 
(LEV) cipro-
floxacin 
(CIP), and 
ofloxacin 
(OFX).
4-6% (CIP), 10-
25%(OFX) and 
10-19% (LEV)
120 – 420 nm N/A Drug release studies show a 
difference between hybrid LEV-
NPs and their non-hybrid 
counterparts. Hybrid LEV-NPs 
showed a burst release in the first 
5h, and then a slow release in the 
following 20h. With non-hybrid 
NPs, almost all of the drug is 
released in the first 5h.
OFX release profiles of hybrid and 
non-hybrid NPs are very similar, 
with 90% of the drug being 
released in the first 5h. 
[49]
Albumin, gelatin 
and chitosan NPs
Ciprofloxacin 48% for 
albumin, and 
35% for 
chitosan. 
Gelatin-
ciprofloxacin 
NPs were found
to be unstable 
and prone to 
flocculation.
140 – 175 nm 
for albumin, 
143 – 184 nm 
for gelatin,  
247 – 322 nm 
for chitosan.
N/A The aim of this study was to com-
pare four different nanosystems: 
SLNs, albumin, gelatin and 
chitosan.
In vitro results showed both albu-
min and chitosan NPs were capable
of prolonged drug release up to 
120h and 96h respectively.
[38]
2.4.2 Liposomes
Liposomes  are  vesicular  structures,  constituted  by  phospholipid  bilayers  enclosing  an  aqueous
medium. They were discovered in 1965 and have been attracting interest as nanocarriers for many
years [26]. They possess a unique and versatile structure, with lipid and aqueous regions, which can
be altered to make them better suited to carry hydrophilic, lipophilic, or both hydrophilic and lipo-
philic particles. Their size can be fine tuned to achieve different regions of the lung  by passive tar-
geting, and their structure and composition can be changed to achieve active targeting to specific
cells, namely AMs. Surface mannosylation is one of the most successful examples of this strategy,
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as it has been shown to increase uptake of liposomes by AMs [51]–[54]. Liposomes seem particu-
larly appropriate  for  pulmonary delivery,  since  they can  be  formulated  from endogenous  com-
pounds,  such  as  the  components  of  pulmonary  surfactant [55].  However,  many  aerosolization
techniques can compromise liposome structure and integrity. In most aerosolized liposome formula-
tions for targeted pulmonary delivery, liposomes are formed before packaging. This usually results
in  rupturing  of  vesicle  structure  during  administration,  thereby losing  the  ability  for  sustained
release. However, it had already been demonstrated that PEGylated and plain Tf-conjugated lipo-
somes  are  stable  enough to  undergo nebulisation  in  the  course  of  an  inhalational  therapy [56].
Recently, Chattopadhyay et al. showed that changing their composition, by incorporation of charged
lipids  and  cholesterol  molecules  into  the  bilayer,  prevented  particle  aggregation  and  preserved
bilayer integrity after air-jet nebulization [57]. Another approach is based on the fact that  a drug–
lipid mixture solubilized in chlorofluorocarbon (CFC) will form liposomes upon hydration in small
airways. Gaur et al. explored the hypothesis of forming liposomes in situ, since the lung has a wet
surface which could provide an aqueous phase for spontaneous formation [58]. They have reported
that no vesicle rupture was observed with in situ formed liposomes, and prolonged drug release was
achieved.
For  all  these  reasons,  it  is  therefore  not  uncommon  to  find  a  vast  number  of  studies
involving pulmonary delivery of drugs with liposomal formulations, many of them focusing on
anti-TB drugs. Ciprofloxacin was one of the first anti-TB drugs to be used with liposomes. Wong,
Finlay and coworkers explored liposomal ciprofloxacin in 1998. They studied liposome disruption
during aerosolization, using 25 nebulizers [59]. Later, they published results on spontaneous forma-
tion of liposomes on dispersion of phospholipid-based powder formulations [60], [61]. With these
liposomes, they achieved entrapment efficiencies of 44% for ciprofloxacin, but the value increases
up to 96% with the incorporation of negatively charged lipids. Bhavane et al. developed liposome
agglomerates that could be triggered by the instillation of a biologically acceptable agent [62]. They
used cysteine as such agent,  and proposed that this  strategy could facilitate post-administration
modulation of the drug release rate. It could allow for treatment regimens where the administration
of one single dose would be sufficient for an extended period of time, since drug release could be
periodically accelerated. They also found that progressive release of the drug does not cause signi-
ficant inflammation, unlike the administration of free ciprofloxacin.
Other anti-TB drugs have already been studied with liposomes. Justo and Moraes studied the
possibility of passive liposomal encapsulation of isoniazid, pyrazinamide, rifampicin, ethionamide,
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and streptomycin [55]. However, under the tested conditions, rifampicin and ethionamide were not
successfully encapsulated. Low encapsulation efficiencies were obtained for isoniazid and pyrazin-
amide, being the encapsulation of streptomycin only higher at a drug to lipid molar ratio of 0.04.
Gaur et al. published a feasibility study where they used rifampicin as the model drug [58]. In this
study,  in situ formed liposomes showed better sustained release profile than the preformed lipos-
somes, but both liposomal aerosols showed improved delivery of rifampicin over plain drug aero-
sols, with encapsulation efficencies around 30%. Liposomes for the delivery of isoniazid have been
developed and evaluated in vitro [63] by Chimote and Banerjee. They observed a sustained release
of isoniazid encapsulated in liposomes, tooking place over 24 h after a burst release in the first 5h.
They have also conducted biocompatibility and stability studies, and found the formulations to be
haemocompatible and cytocompatible, and stable for the duration of at least one month.
The possibility of surface coating to achieve active targeting with liposomes has also been a
subject  of  interest.  Vyas  et  al. used  rifampicin  when  studying  liposomes  coated  with  macro-
phage-specific ligands, and reported a preferential accumulation of lingad-coated formulations in
the lung macrophages, namely MBSA and O-SAP coated liposomes [64]. In vivo tissue distribution
studies are on par with these results, by showing higher lung drug concentration for ligand-coated
liposomes.  O-SAP surface modification was also the focus of Deol and Khuller, who  developed
coated liposomes for the encapsulation of both rifampicin and isoniazid [65]. They compared the
results with uncoated ones, and reported that encapsulating drugs within liposomes reduced toxicity,
and that  O-SAP coating succeeded in enhancing lung accumulation. Tuftsin functionalization of
liposomes encapsulating rifampicin was studied by Agarwal  and coworkers [66].  They reported
interesting results: considering one single administration, tuftsin functionalization did not give bet-
ter results than uncoated formulations, but with regular administration over two weeks, tuftsin lipo-
somes were more efficient in controlling tuberculosis.
The use of aerosolized liposomes as vaccines to fight TB is a different strategy already con-
sidered. Dascher  et al. incorporated lipids from MTb into liposomes, and administrated them to
guinea pigs [67]. They succeeded in reducing bacterial burden in the lung, but regarding the spleen
results were not statistically significant. Moreover, lipid-vaccinated lungs showed significantly less
pathology, with granulomatous lesions being smaller and more lymphocytic.
Gene therapy has also been the subject of many studies with liposomes for the past twenty
years,  but  despite  these  efforts,  little  progress  towards  developing  an  effective  pharmaceutical
product has been done, and the vast majority of clinical trials still uses viral delivery of DNA, a
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much more effective approach, despite the associated toxicity issues [68]. There is ongoing research
to address these problems. One recent study used single-tailed cationic lipid 6-lauroxyhexyl lysinate
(LHLN) to prepare cationic liposomes, and  in vivo results showed that, compared with commer-
cially available  Lipofectamine2000/DNA complexes,  LHLN-liposomes exhibited lower cytotox-
icity,  and higher pulmonary gene transfection efficiency [69].  Table 2 summarizes the currently
found studies with liposomes as carriers for anti-TB drugs.
Table 2: Liposomes for the encapsulation of anti-TB drugs
Particle(s) Drug(s) Loading 
efficiency
Size Ligand  In vitro/in vivo results Ref.
Multilamelar 
liposomes 
(PC:Chol)
Rifampicin 47 –  49% 2 – 4 µm Negatively 
charged liposomes
(DCP), PE–
MBSA conjugate 
and O-SAP .
Lung retention of rifampicin 
was higher with liposomes than
with free drug. The highest 
value for lung retention was 
measured in ligand coated 
liposomes.
[64]
Pre formed and 
in situ formed 
liposomes
(EPC:Chol:DCP)
Rifampicin 29 –  38% 2 and 1µm for 
preformed and 
in situ formed, 
respectivelly
N/A There is no indication of 
ruptured vesicles for in situ 
formulations, and prolonged 
drug release is achieved.
In situ formulations do not 
show any adverse effect on 
discharge patterns.
[58]
Liposomes
(DSPC:Chol)
Isoniazid, 
pyrazinamide, 
rifampicin, 
ethionamide, 
and 
streptomycin.
3% for 
isoniazid, 2% 
for 
pyrazinamide, 
0% for 
streptomycin 
and 
rifampicin, 
and 42% for 
ethionamide 
(although only
at a drug to 
lipid molar 
ratio of 0.04).
286 – 329 nm N/A N/A [55]
Multilamellar 
liposomes
(DPPC)
Isoniazid ~37% 750 nm N/A About 50% liposome entrapped
isoniazid released in vitro at the
end of 5 h and remaining drug 
was released slowly over 24 h. 
[63]
Liposomes 
(PC:Chol)
Ciprofloxacin 90% (before 
nebulization), 
of which 2 – 
30% remained
entrapped after
nebulization, 
depending on 
the nebulizer 
used.
5 – 7 µm N/A N/A [59]
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Table 2: Liposomes for the encapsulation of anti-TB drugs
Particle(s) Drug(s) Loading 
efficiency
Size Ligand  In vitro/in vivo results Ref.
Liposomes
(DPPC:Chol and 
EPC:Chol)
Ciprofloxacin 97% before 
lyophilization,
of which up to
90% were 
retained by the
lyophilized 
cake, and up 
to 40% after 
jet milling.
1 – 7µm 
(lyophilized 
cake);
1 – 2 µm (after 
jet milling) 
N/A N/A [60]
Liposomes 
(DPPC:CHOL: 
DSPE-MPEG 
and 
DPPC:CHOL:DS
PE-PEG- 
NH2)
Ciprofloxacin N/A 140 – 460 nm 
for liposomes, 
depending on 
formulation.
 1 – 140 µm for
agglomerates 
(AVT1 and 
AVT2).
N/A In vitro studies showed 
liposomes, AVT 1, and AVT 2 
had an initial burst in release of 
drug, but it was much lower 
than that for free ciprofloxacin, 
and were capable of extended 
drug release in the blood. 
After instillation of cysteine at 
90 minutes into the lungs of the
rabbits treated with AVT 2, an 
elevation in release rate was 
observed. 
[62]
Liposomes 
(DSPC:Chol)
MTb whole-
lipid extract 
incorporated 
in the 
liposomes
N/A < 300 nm N/A Lipid-immunized animals 
showed reduced bacterial load 
in the lung, but no statistically 
significant decreases in the 
spleen.
Lesions in the lung tissue of 
lipid- and BCG-vaccinated 
animals were smaller, less 
necrotic and more lymphocytic.
[67]
Liposomes 
(DMPG, 
EPC:DMPG, and
DMPC:DMPG)
Ciprofloxacin Above 90% 
and around 
50%, before 
and after 
nebulization, 
respectively.
2 – 3 µm N/A N/A [61]
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Table 2: Liposomes for the encapsulation of anti-TB drugs
Particle(s) Drug(s) Loading 
efficiency
Size Ligand  In vitro/in vivo results Ref.
Liposomes 
(EPC:Chol)
Isoniazid, 
rifampicin
8 – 10% for 
isoniazid.
 44 – 49% for 
rifampicin.
≥200 nm for 
O-SAP coated 
liposomes. 
<200nm for 
DSPE-PEG 
liposomes.
O-SAP Encapuslated drugs were found 
to be less toxic than free drug. 
Drug uptake in macrophages 
was found to be similar 
between encapsulated and free 
drugs.
Slow and controlled drug 
release was achieved in encap-
sulated drugs.
O-SAP coating enhanced lung 
accumulation. Also, pre-admin-
istration of PC and Chol  lipo-
somes before the injection of 
lung specific stealth liposomes, 
further enhanced their uptake in
lungs. 
[65]
Liposomes (EPC) Rifampicin. 28 – 32% 25 – 65nm Tuftsin With 10 mg/kg dose of lipo-
somal RIF, a significant reduc-
tion in the lung bacillus load 
and an increase in MST were 
observed, compared with those 
in free RIF treated animals. 
Regarding tuftsin functionaliza-
tion, one single treatment with 
coated liposomes was only mar-
ginally better than that observed
with uncoated ones, but coated 
liposomes given twice weekly 
for 2 weeks was considerably 
more effective than uncoated 
ones in controlling  TB.
[66]
2.4.3 Drug nanocrystals
The pure use of therapeutic agents in the form of nanocrystals has been proposed as a system for
drug delivery. They are used as dispersions of pure drug nanoparticles kept stable through the pres-
ence of a minimum amount of a surfactant – nanosuspensions. Drug nanocrystals dissolve rapidly in
the lung lining fluid leading to a high concentration, which is helpful for localized treatment of res-
piratory diseases such as pulmonary TB. Results show that these could be used in drug delivery for-
mulations  to  improve  pharmacokinetic,  pharmacodynamic  and  targeting  properties  of  poorly
soluble drugs.  Gao et al. reported two different kinds of pulmonary formulations containing drug
nanocrystals [28]: aqueous nanosuspension packaged and administered by a nebulizer; drug nano-
crystals  collected  and transported  into the lung by the  small  aerosol  droplets  generated  by the
nebulizer. 
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Spore like drug particles for deep lung deposition have also been proposed as an innovative
system [70]. Hollow and spore like nanoagglomerates were obtained by mixing the drug solution
with an antisolvent in a high gravity environment. The fabrication of drug particles similar to spores
may improve the pulmonary drug delivery efficiency in DPIs, and is a more efficient, cost-effective
and easy to scale up method over milling, homogenization, spray freezing into liquid, and supercrit-
ical antisolvent precipitation to prepare nanosuspensions. According to the authors, uniform particle
size and controlled morphology can be achieved with this technique.
Currently, only one report was found regarding the production of nanocrystals or nanoagglom-
erates of an anti-TB drug. El-Gendy et al. prepared ciprofloxacin nanosuspensions that were then
flocculated to form nanoparticle agglomerates [71]. Nanoparticle size ranged from 68 – 722 nm,
depending on the formulation, and agglomerates exhibited a particle size range of 2 – 4 μm. They
performed dissolution studies, and compared the results with the stock drug. Results showed that
the dissolution rate was improved, demonstrating that these techniques may help to overcome some
of the solubility issues presented by new anti-TB drugs, specially by molecules that, although did
not pass from the clinical trials due to solubility issues, shown higher potential as anti-TB drugs.
2.4.4 NPs with effervescent activity
Nanoparticles with effervescent activity have recently been suggested for pulmonary delivery. Oral
drug delivery associated with effervescent pharmaceutical formulations is used for a long time, in
stomach distress medications, vitamin supplements and analgesics. Effervescent activity of the car-
rier particles occurs when the carrier particles are exposed to humidity, adding an active release
mechanism to the pulmonary route of administration.  Additionally,  effervescent particles can be
synthesized with adequate size for deep lung deposition, and the technology appears to be safe for
pulmonary delivery [72].
Although  effervescent  NPs  have  been  mostly  studied  as  a  promising  pulmonary  delivery
strategy for anti-cancer drugs [72]–[74], one report has been found regarding their use for the deliv-
ery of ciprofloxacin [75]. Ely and coworkers have developed and studied different powder composi-
tions with effervescent activity, and found two formulations suitable for pulmonary delivery. These
formulations had the addition of l-leucine and PEG 6000, which improved the aerodynamic charac-
teristics of the powder particles. Effervescent activity of the prepared formulations resulted in the
release of nanoparticles  with less agglomeration compared to  the carrier  particles  made just  of
lactose.
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Table 3: Other nanosystems for the delivery of anti-TB drugs
Particle(s) Drug(s) Loading 
efficiency
Size Ligand  In vitro/in vivo results Ref.
Drug nano-
particle agglom-
erates
Ciprofloxacin 81 – 96% 68 – 722 nm for 
NPs;
2 – 4 μm for NP 
agglomerates
N/A N/A [71]
PBCA
Effervescent NPs
Ciprofloxacin N/A Carrier particles: 
2µm
Effervescent 
preparations:
244 and 252 nm 
before and after 
spray drying, 
respectively. 
Effervescent 
preparations 
containing l-
leucine and PEG 
6000: 150 and 
177 nm, before 
and after spray 
drying, 
respectively.
N/A Effervescent carrier particles 
released 56% ciprofloxacin into 
solution compared with 32% when
lactose particles were used.
[75]
2.4.5 Gold and magnetic NPs
Gold NPs have recently been used to study internalization and intracellular translocation of inhaled
nanoparticles in rat  AMs [76]. Particles used had mean hydrodynamic radius of 16 nm. Results
showed AMs had efficiently internalized NPs by endocytosis. Gold NPs have been conjugated with
streptomycin [77], and it has been demonstrated that ciprofloxacin binds to gold NPs [78], but the
cited studies do not focus on pulmonary delivery, and no other reports have been found regarding
the use of these particles for pulmonary delivery, regardless of the model drug.
The use of magnetic aerosols using superparamagnetic iron oxide NPs has also been suggested
as a way to improve drug delivery to the lung [79], and ciprofloxacin has been used as a model drug
in the development of superparamagnetic nanocomposites with magnetically mediated release of
the loaded anti-TB drug [80]. However, no study has been found combining these two strategies to
achieve magnetically mediated pulmonary delivery of anti-TB drugs.
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2.4.6 Lipid NPs
Lipid NPs are the last nanosystems presentd in this state of the art and are the focus of this thesis.
Generally speaking, and by contrast with liposomes and polymeric nanoparticles, lipid NPs show
higher drug loading capacity,  higher  stability,  and require the use of lower amounts of organic
solvents during production [81]. As with liposomes and most polymeric NPs, these nanocarriers are
biocompatible and can be produced with appropriate size and morphology for lung targeting and
deposition [82], and have been studied as a viable pulmonary drug delivery strategy [83]. It is also
possible to modify the surface of lipid NPs to achieve active targeting of AMs. Mannose is a com-
mon surface modification with lipid nanocarriers [84].
Solid lipid nanocarriers  (SLNs) and nanostructured lipid carriers  (NLCs) are  the two most
common lipid NPs used. The published results by Jain and coworkers, who compared four different
nanocarriers for the incorporation of ciprofloxacin,  showed that SLNs are capable of prolonged
drug release [38]. This work is one of the three reports that were found regarding pulmonary deliv-
ery of SLNs loaded with drugs for the treatment of TB, namely rifabutin, isoniazid, rifampicin and
pyrazinamide. Nimje  et al. prepared rifabutin loaded SLNs, and compared uncoated formulations
with formulations coated with mannose [24]. Results showed cellular uptake in AMs was almost six
times enhanced due to mannose coating. Coated formulations also showed to be less immunogenic
and more suitable for sustained delivery. Pandey and Kuller have prepared SLNs for pulmonary
delivery through nebulization [85].  They incorporated isoniazid,  rifampicin and pyrazinamid,  of
which rifampicin showed the highest incorporation due to the lipid-based nature of the formulation
and lipophilic characteristics of the drug. The nebulized SLNs were successfully deposited in the
lungs, and were detected in other organs up to 7 days after administration. Administrated free drug
was cleared from the system within 24 – 48 h. Jain and Banerjee included SLNs in their list of
nanosystems to deliver ciprofloxacin, and concluded that these NPs were suitable for drug loading,
and capable of sustained drug release [38].
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The matrix of SLNs consists of solid lipids only, with perfect crystallinity. This results in lower
drug loading, since there are very few empty spaces in which the drug can be found. It also results
in expulsion of drug content during long storage due to changes in lipid packaging. NLCs are differ-
ent structures. The matrix consists of both solid and liquid lipids, consequently showing lower crys-
tallinity and higher incidence of nanostructures, which won't result in denser lipid packaging over
time. Thus, higher drug loading and stability during long storage is achieved, when compared with
SLNs [86].  Figure 6 illustrates the differences in the matrix of SLNs and NLCs, and the overall
influence of such differences in drug loading and expulsion over time. However, it should be noted
that no study was found regarding the use of NLCs as carriers for any anti-TB drug. Table 4 sum-
marizes currently found studies regarding the use of lipid nanoparticles for the treatment of TB.
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Figure 6: Schematic representation of the matrix of SLN and NLC.
A:SLN exhibits a high order matrix, while NLC exhibits a low order matrix. B: Drug is loaded into SLNs and NLCs. C: 
Over time, SLNs tend to a denser lipid packaging and higher drug expulsion than NLCs.
Development and Characterization of Nanocarrier Systems for the Delivery of Antitubercular Drugs
Table 4: Lipid NPs for the incorporation of anti-TB drugs
Particle(s) Drug(s) Loading 
efficiency
Size Ligand  In vitro/in vivo results Ref.
SLN
(tristearin)
Rifabutin 82% 
(uncoated) 
and 87% 
(coated)
251 nm 
(uncoated) and
389 nm 
(coated)
Mannose In vitro studies showed a 
sustained drug release for 120h,
during which uncoated SLNs 
showed higher drug release. 
Macrophage uptake was higher 
for coated SLNs.
In vivo results showed higher 
drug presence for coated SLNs 
in the lungs.
[24]
SLN 
(Stearic acid)
Isoniazid, 
rifampicin and
pyrazinamid
51% for 
rifampicin, 
45% for 
isoniazid and 
41% for 
pyrazinamide.
1 – 2 µm N/A In vitro results varied for 
simulated gastric or intestinal 
fluid. The drug released was 
<20% in the first 6 h and 11–
15% during 6–72 h for 
isoniazid/pyrazinamid; 9% in 
the first 6 h and 11% during 6–
72 h for rifampicin, although 
rifampicin release was in the 
range of 8–12% during the 
entire study period for intestinal
fluid.
All the three drugs could be 
detected in the lungs, liver and 
spleen of the animals up to day 
7 following the nebulization.
[85]
SLN
(stearic acid)
Ciprofloxacin 39% 74 – 99 nm N/A The aim of this study was to 
compare four different nanosys-
tems: SLNs, albumin, gelatin 
and chitosan.
In vitro results showed SLNs 
were capable of a prolonged 
drug release up to 80 h.
[38]
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3 Materials and Methods
3.1 Development of Nanostructured Lipid Carriers
3.1.1 Initial formulation
NLCs were initially prepared with with Cetyl Palmitate (C32H64O2; M=480.83 g mole
-1; Gattefossé)
as  the  solid  lipid,  and  Mygliol  812  (from  Acofarma)  as  the  liquid  lipid.  Polysorbate  60
(C64H126O26; M=1 310 g mol
-1; Sigma Aldrich) was used as surfactant, to stabilize the emulsion.
Quantities used for each are presented in table 5:
There are several methods to produce NLCs in the laboratory, such as high pressure homogenization,
microemulsion technique, emulsification-solvent evaporation, emulsification-solvent diffusion method,
solvent injection (or solvent displacement) method, phase inversion, multiple emulsion technique, ultra-
sonication and membrane contractor technique [86].
In the present work, an ultra-sonication method was used. In detail, the two lipids and the surfact-
ant were heated in a water bath up to 70º C, temperature at which both lipids are in the liquid state.
When the solid lipid was fully melted, 4.4 mL of heated ultrapure water (T = 70º C) was added to
the mixture. Mixture then went through ultraturrax (Ystral X10/20 E3) at 3500 rpm for 30 s, and
sonication  (Sonics  Vibra-cell,  with  CV18 probe)  at  70% power for  5 min,  which  resulted  in  a
nanoemulsion. This nanoemulsion was finally left to cool at room temperature and stored. Figure 7
features a schematic representation of the process.
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Mass / mg
Cetyl palmitate 350
Mygliol 812 150
Polysorbate 60 100
Formulations prepared with 4.4 g of ultrapure water.
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3.1.2 Drug Loading
Two anti-TB drugs were used in the present work,  one first-line drug (RIF) and one second-line
drug (RFB). A third first-line drug (isoniazid) was considered, but its high hidrofilicity rendered it
unsuitable  for  lipid  NPs.  RIF (C43H58N4O12;  M=822.94  g  mol ¹;  Sigma  Aldrich)  ⁻ and  RFB
(C46H62N4O11; M=847.00468 g mol ¹; ⁻ Sigma Aldrich) are lipofilic molecules, and in principle suit-
able to be loaded with high efficiency in lipid NPs.
Drug content in loaded NLCs (NLC-RIF and NLC-RFB) was added (~7 mg) to the lipid mix-
ture prior to the melting stage. When the melted lipid mixture and the drug form a homogeneous
liquid  mixture,  ultra-pure  water  is  added,  followed  by ultraturrax  and  sonication,  as  described
before.
3.1.3 Choice of solid lipid for improved drug loading
Drug loading and release are essential parameters to evaluate a drug delivery system. Solubility of
the drugs in the lipid mixture plays a major role in the amount of drug a nanosystem can be loaded
with. When it comes to lipid NPs, it is important to choose lipids where the used drugs exhibit high
solubility. For this purpose, qualitative solubility studies where performed to choose a solid lipid
that would yield better results than the initially used Cetyl Palmitate.
In brief, the same amount of rifampicin was added to the same amount of five solid lipids:
Cetyl Palmitate, Dynassan 116, Compritol 888 ATO, Golucire 43/01, Precirol ATO 5 (all lipids from
Gattefossé). Lipids Compritol 888 ATO and Precirol ATO 5 both gave satisfactory results, showing
the highest solubility for the used drugs. However, Compritol 888 ATO has a much higher melting
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Figure 7: A schematic representation of the steps performed to develop simple NLCs.
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point (above 70 ºC) and it was deferred in favor of Precirol ATO 5. The final lipid mixture used in
the formulation was Precirol ATO 5 as the solid lipid, and Mygliol 812 as the liquid lipid.
3.1.4 Mannose coating
As described in detail in the state of the art, mannose (C6H12O6; M=180.16 g mol-1) has already been
used to enhance uptake by AMs with gelatin NPs [40], liposomes [51] and SLNs [24], and it was
chosen as the ligand in the presented work to achieve active targeting.
Coating of NLCs with mannose  (NLC-M)  was initially
adapted from the methods described by Jain et al. for SLNs
used for site specific delivery of anti-cancer drugs [87]. First,
NLCs were modified in order to exhibit amine groups at the
surface.  To  achieve  this,  stearyl  amine  (Octadecylamine;
C18H39N; M=269.51 g mol-1; Sigma Aldrich) was added to the
lipid mixture described at 3.1.3, and the resulting mixture was
dissolved in acetone:ethanol (1:1 v/v) at  70ºC. An aqueous
phase was prepared, containing the surfactant and the drug.
The lipid phase was slowly mixed with the aqueous phase, at
70ºC, using a micropipette, while slowly agitating. The mix-
ture was then ultraturraxed and sonicated as described before.
For  mannosylation  of  NLCs,  a  mannose  (Sigma  Aldrich)
solution (50 mM) was prepared in acetate buffer (pH = 4),
and subsequently added to the NLC suspension and left under
constant and gentle stirring for a period of 48h. The rationale
behind this procedure follows: the acidic environment would
result in the ring opening of the mannose molecules; the alde-
hyde group would then react with free amine present at the
surface of the stearyl amine functionalized NLCs, leading to
the formation of a Schiff's base (–N=CH–) (Figure 8), which
can be detected using Infrared Spectroscopy.
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Figure 8: Schematic representation of method 
for mannosylation of SLNs.[87]
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This first method resulted in a very thick formulation, and modifications were performed to achieve
a workable liquid suspension, as well as to try to avoid using an organic solvent in the process
(acetone). The final method consisted in the development of the NLCs as described in 3.1.1, with
the lipid mixture stated in 3.1.3, to which the drug content was added. Afterwards, the solution of
mannose in acetate buffer was added to the NLC suspension, together with stearyl amine. The mix-
ture was then left under constant and gentle stirring for a period of 48h. Finally, the resulting sus-
pension was washed through dialysis in ultra-pure water for 30 min, using a regenerated cellulose
tubular  membrane  (CelluSep  T3;  Nominal  MWCO: 12  000 –  14  000;  Wall  thickness:  20 μm;
Orange Scientific), to remove any excess mannose and stearyl amine. Figure 9 shows a schematic
representation of the final process to achieve mannose coated, drug loaded NLCs.
3.1.5 Lyophilization
Lyophilization (or freeze-drying) is the process of removing water from a frozen sample, using sub-
limation and desorption under vacuum. Many pharmaceutical products, mainly heat sensitive com-
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Figure 9: A schematic representation of the final process to achieve mannose coated, drug 
loaded NLC suspension.
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pounds, are dried using this technique, since it improves the long-term physico-chemical stability
and prevents degradation reactions such as hydrolysis. Lyophilization is also used with NPs to pre-
vent particle aggregation [88].
Liofilization was the final step of the present formulation,  not only to improve physico-
chemical  stability,  prevent  degradation  and particle  aggregation,  but  also to  allow a  successful
detection the Schiff's Base (thus confirming mannose coating) using Infrared Spectroscopy, and to
provide a better material to perform citotoxicity studies, since re-suspension could be done using
cell medium. The quality of the lyophilized product is highly dependent on the parameters of the
process. The ideal lyophilization parameters for NLCs were based on the literature. Varshosaz et al.
performed an exhaustive study on lyophilization parameters of NLCs, experimenting with various
temperatures, pressures and cryoprotectants [88]. Considering the differences in materials available,
a lyophilization process for NLCs was adapted from the procedure considered ideal by Varshosaz
and coworkers.
A VirTis freeze dryer (Advantage Plus EL-85; SP Scientific) was used in this process. Samples
were prepared with Aerosil 2% (m/m) as cryoprotectant. Initial freezing was done at – 60 ºC for
720 min. Condensatin was made at – 80 ºC under 150 mTorr of pressure. Drying was done at 20º C
for 1 200 min, under 150 mTorr of pressure. Secondary drying was performed at 25 ºC, for 1 200
min, under 100 mTorr of pressure.
3.2 Characterization
3.2.1 Particle Sizing
To determine the size of the developed NLCs, dynamic light scattering (DLS) – also called photon
correlation spectroscopy – was used. The advantages of using this technique over other techniques
to determine the average size of a large population of spherical particles include the short time
required to perform the measurements, the statistical validity of the results and the relatively low
cost of the necessary devices. There are, however, drawbacks, such as the influence in the results of
dust particles and nanoparticle aggregation [89].
The  determination   of  particle  size  by DLS works  by studying  the  scattering  of  light  by
particles  in  suspension,  assuming they are  spherical  in  geometry and animated  with  Brownian
motion. In a typical DLS experiment, a beam of polarized light, usually a LASER, passes through a
scattering  medium.  A detector  measures  the  scattered  light  at  a  fixed  angle,  called  scattering
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angle θ [90]. Due to Brownian motion, there are fluctuations in the intensity of the scattered light,
which can be measured and then interpreted by autocorrelation,  using the following correlation
function:
 g2(q , t)=
1
〈 I 〉2
lim
T →∞
1
T∫0
T
I (q , t)I (q , t+ τ )dτ − 1 (1)
where I is the scattered light intensity, <I> is the temporal average scattered light intensity and t is
the acquisition time, q is the scattering vector defined as q = (4πn/λ)sin(θ/2), being n the refraction
index of the solvent, λ the light wavelength and θ the scattering angle. We can determine the field
autocorrelation function g1 through the Segret relation g2 = | g1|2. For monodisperse non-interact-
ing particles in Brownian motion, this function is a simple decreasing exponential with a relaxation
rate Γ (Γ = 1 / τ, τ = decay time)[91].
This relaxation rate is obtained by curve fit, and can then be related to particle size. To do so, it
is necessary to determine the coefficient diffusion of suspended particles, which is one of the pro-
cesses of Brownian motion. Brownian motion is a random, microscopical movement, which results
from thermal fluctuations in the fluid medium. In his seminal paper, Einstein stated that one of the
processes that determines particle movement in a suspension was “a process of diffusion, which is
to be looked upon as a result of the irregular movement of the particles produced by the thermal
molecular movement”, and he then proceeded in defining the coefficient of diffusion (D) for spher-
ical particles as:
D=
K B T
6π ηrh
 (2)
where KB is the Boltzman's constant (minding that KB=R/NA), T is the temperature of the medium,
η is the fluid's viscosity,  and  rh is the hydrodynamic radius [92], in which one is interested for
particle sizing. Relaxation rate relates to coefficient diffusion through the equation:
Γ=qD²  (3)
So, by experimentally determining Γ, we can determine particle size in suspension by using equa-
tions (2) and (3). For monodisperse solutions, g1 has only one exponential decay, but for polydis-
perse solutions, g1 shows several exponential decay components, and interpretation of DLS data
requires either cumulant or multi-exponential analysis [91]. Modern DLS particle sizing apparatus
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are already equipped with autocorrelators, are fully automated, and able to determine particle size
and polydispersity index (PDI) of nanosuspensions.
In the present work, particle size was measured using a BI-MAS DLS instrument (Brookhaven
Instruments, USA), operating at scattering angle of 90°, a temperature of 25 °C, pH 7.4, with dust-
cutoff set to 30. At each measurement, 6 runs of 2 min each were performed. Prior to the measure-
ments, formulations were diluted (1:100) and filtered with a syringe filter (800 nm).
3.2.2 Zeta potential
Due to their large surface area/volume ratio, the
properties of the surface of nanoparticles play an
important role in their overall properties, such as
particle-particle interaction and particle-cell inter-
action.  One of this  properties  is  surface charge,
yet, it is difficult to achieve satisfactory measure-
ments,  directly  or  otherwise,  of  surface  electric
potential [93].  Other  than  that,  such  potential
causes a binding of water molecules and ions to
the  nanoparticle  surface,  creating  a  layer  that
moves  along  with  the  nanoparticle [94,  Ch.  5].
Thus, it becomes important to determine the elec-
tric potential at a certain distance of the surface,
characterized  by the  length  of  this  layer,  at  the
called slipping or shear plane. The electric poten-
tial at this distance is called the electrokinetic or Zeta (ζ) potential [95] – see figure 10. ζ-potential
plays an important role in the stability of colloidal systems, and shelve stability is an important
factor to consider when developing a new drug delivery system [96].
One of the most used methods to determine ζ - potential of suspended particles, and the one
used in the present work, is the method of Electrophoretic Light Scattering (ELS) [93]. Since it is
also a light scattering technique, it  can be performed in the same apparatus as the one used for
particle sizing.
In DLS, particle size is determined by measuring fluctuations in the intensity of scattered light
due to Brownian motion of the suspended particles (see previous section). In ELS, two electrodes
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Figure 10: Illustration of variations in the electric potential 
from the surface of a nanoparticle.[102]
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generate an electric field, which results in a movement that overlaps Brownian motion. The fre-
quency in scattered light thus shifts due to Doppler effect (Figure 11), and that shift (Δω) can be
used to calculate particle drift velocity, through the equation:
Δ ω=q . vd  (4)
where q is the scattering vector already discussed in the previous section. The magnitude of drift
velocity is proportional to the electric field (E) by a constant, μ, which is defined as the electrophor-
etic mobility of the particle:
vd=μ×E  (5)
Finally,  the ζ-potential can be calculated from the electrophoretic mobility,  taking electrokinetic
properties of the medium into account, through mathematical models. One of these models, and the
one used in this work, is the Smoluchowski equation:
ζ=
ημ
ε0ε  (6)
where η is the viscosity of the medium, ε0 is the permitivity of vauum, and ε is the dielectric con-
stant of the medium [97].
ζ-potential of NLCs was measured using a BI-MAS DLS instrument (Brookhaven Instruments,
USA), operating at scattering angle of 90°, a temperature of 25 °C, pH 7.4. For each measurement,
10 runs were performed.
3.2.3 Particle morphology
Scanning Electron Microscopy (SEM) was used to observe particle morphology. In electron micro-
scopy, a beam of charged particles (electrons) is used instead of a beam of photons (used with
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Figure 11: Frequency shift of scattered light due to 
movement of suspended particles when subjected to an 
electric field.
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optical microscopy).  These particles provide beams with high energy,  thus shorter wavelengths,
hence allowing an observation of objects in the nanometric scale. In SEM, this beam interacts with
small areas of the sample, and secondary electrons (among other particles) are scattered from it.
These electrons are detected and the beam proceeds in scanning the rest of the surface. Gathered
data can then be used to reconstruct the sample's morphology. The signals obtained with SEM also
allow for the determination of chemical composition, crystalline structure and orientation of materi-
als making up the sample [98].
For the present work, the SEM exam was performed using a high resolution Scanning Electron
Microscope with X-Ray Microanalysis and CryoSEM experimental facilities:  JEOL JSM 6301F/
Oxford INCA Energy 350/ Gatan Alto 2500. The specimen was rapidly cooled (plunging it into sub-
cooled nitrogen – slush nitrogen) and transferred under vacuum to the cold stage of the preparation
chamber. The specimen was fractured, sublimated (‘etched’) for 120 sec. At –90 °C, and coated
with Au/Pd by sputtering for 45 sec. The sample was then transferred into the SEM chamber, and
studied at a temperature of -150 °C.
3.2.4 Loading efficiency
The efficiency with which an active agent is incorporated into a carrier matrix can be expressed as a
percentage, which is referred to as the loading efficiency (LE), and is calculated using the following
expression:
LE=
T D−U D
T D
×100  (7)
where TD is total drug and UD is unentrapped drug (drug dissolved in water medium).
The loading capacity (LC), which is the capacity of an encapsulation system to carry a drug,
can be calculated by the expression:
LC=
ED
ED+matrix
×100  (8)
where ED is the drug entrapped in the nanosystem. 
The amount of drug dissolved in water medium can be quantified by UV-Visible spectroscopy,
which allows relating absorbance of radiation at a specific wavelength with the concentration of the
dissolved drug.
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When electromagnetic radiation interacts with matter, energy transfer may occur in many ways.
In one of them, electrons in the electron cloud will absorb incident photons, as long as they have the
exact same energy as it would be necessary to promote the transition from one energy level to an
upper one, changing the atom or molecule's quantum mechanical states. The allowed energy levels
are quantized, and are specific of the chemical species [99].
The energy of an electromagnetic wave, E, is related to it's frequency, f, by the expression:
E=h. f= c hλ  (9)
where  h is Planck's constant. Since f=c/λ, where  c is the speed of light in vacuum and λ is the
wavelength of radiation. It is therefore possible to identify elements in samples by determining for
which wavelengths photons are highly absorbed from an incident beam. This set of wavelengths
constitutes an absorption spectrum [100]. Absorbance of a solution is proportional to the solute's
concentration, as is expressed by Beer-Lambert's law:
A=abc  (10)
where c is the solute's concentration, b is the length of solution the beam has to cross, and a is a pro-
portionality constant.  A calibration curve is usually obtained by preparing several samples, with
increasing, well known concentrations, and obtaining their absorption spectrum. Prominent  local
maximums, indicating high absorbance at specific wavelengths, are identified. For the wavelength
at a specific  local maximum, and  ab being constant, absorbance is plotted against concentration,
and a linear fit should be obtained. The resulting equation is then used to determine the mass con-
centration of a sample, through measuring the absorbance at that particular wavelength, provided
the expected concentration is inside the range used for calibration [100].  A modern spectrophoto-
meter does an automatic and highly precise wavelength sweep, meaning it automatically changes
the wavelength of the incident beam by controlling a monochromer.
The first step in the determination of incorporated drug, was to obtain a calibration curve from
drug solutions with known concentrations. The determination of the concentration of the two drugs
used in  the present  work was done  with  a  spectrophotometer  (Jasco V-660) using quartz  cells.
Wavelength interval ranged from 200 nm to 700 nm, with 1.0 nm intervals. The prepared concentra-
tions of drug to determine the linear fit are presented in table 8 for RIF and in table 9 for RFB.
The second step consisted in separating the NLCs from their supernate, and then measuring the
drug content of the supernate (non-loaded drug). To achieve this, formulations were diluted and
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centrifuged inside centrifugal filter units (50 000 NMWL, Milipore corporation, Ireland) for 5 min
at 3 500 RPM. Supernate was collected and it's drug content determined as explained before.
3.2.5 Schiff's base detection by FTIR spectroscopy
As stated before, mannose coating was done by bonding of the open chain mannose with amine ter-
minations in the surface of the NLCs through a Schiff's base (see section 3.1.4). Fourier Transform
Infrared (FTIR) spectroscopy was used to detect Shiff's base and confirm coating with mannose.
FTIR spectroscopy is a technique similar to UV-Vis spectroscopy. The main differences between the
two techniques reside in the wavelength of the incident beam and in the mathematical treatment of
the raw data. UV-Vis spectroscopy works in the ultraviolet and visible ranges of the electromagnetic
spectrum,  while  FTIR,  as  the  name  suggests,  works  in  the  infrared  range.  The  difference  in
wavelength translates in a difference in energy, and FTIR spectroscopy is therefore able to detect
energies  associated  with  specific  bonds  inside  molecules.  The  second  mentioned  difference  is
related  with  how  the  data  is  obtained.  In  UV-Vis  spectroscopy,  beams  of  very  well  defined
wavelengths are used for each measurement. With FTIR spectroscopy, broadband beams, containing
full spectrum of wavelengths, are used for each measurement. Following measurements use differ-
ent spectra. The translation of raw data into absorption for each wavelength requires mathematical
processing, and a Fourier transform is used. The fact that a full spectrum of wavelengths is used
instead of a single wavelength beam, renders this technique faster than conventional spectroscopy.
FTIR analysis of the samples was done with a Frontier FTIR Spectrometer with universal ATR
Diamond/ZnSe accessory (Perkin Elmer, USA). Samples were lyophilized as described in section
3.1.5 before FTIR analysis. Lyophilized samples were placed in ATR accessory and samples were
measured from wavenumber 600 to 4 000 cm-1, 50 scans per sample, with a resolution of 4 cm-1.
3.2.6 Citotoxicity
Citotoxicity of the developed formulations was studied using MTT (3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide) assays with three different cell lines:  Calu-3 (upper respiratory
tract epithelium); A529 (lower respiratory tract epithelium ) and Raw (macrophage cell lines). MTT
is a water soluble salt. Cleavage of the tetrazolium ring of MTT by succinate dehydrogenase within
the mitochondria results in the formation of an insoluble purple dye, which is impermeable to cell
membranes. For this reason, the dye accumulates in the interior of non damaged cells. This insol-
uble dye can be collected and dissolved, resulting in a colored solution. Through the measurement
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of the absorption of light of this solution at a specific wavelength through spectroscopy, it becomes
possible to determine the amount of cells killed by a given process [101].
MTT assay was performed in the course of three days. In the first day cells were seeded to the
60 interior wells of a 96 well plate (the 36 exterior wells were filled with PBS), through the follow-
ing  procedure.  Cells  were  cultivated  in  T25  flasks  with  Dulbecco's  Modified  Eagle  Medium
(DMEM) + Glutamax, complemented with PenStrep, Fungizone and Fetal Bovine Serum (all from
Gibco, Life  Technologies). When confluency was reached, cell medium was removed, and flasks
were washed two times with phosphate buffer saline (PBS) solution, and medium was added. Cells
were then detached from the flask's surface. For Raw cell lines, this was done using a scraper. To
detach Calu-3 and A549 cells, a tripcine solution was added and the flasks were put to rest for 5 min
at 37 ºC. Medium with suspended cells was pipetted to falcon tubes, that were then centrifuged
(1 500 rpm, 5 min, 4 ºC) to separate medium with tripcine from the cell's pellet. Cells were then
resuspended in DMEM. All cells were then counted using the tripanblue explosion method, with a
Neubauer chamber, and cell suspensions were diluted to obtain concentrations of 25 000 cells mL-1.
Finally, each suspension was added to each of the 60 wells, to achieve an approximate concentra-
tion of 5 000 cells/well. Cell plates were left to rest for 24 hours, at 37 ºC.
In the second day, medium from wells was removed and cells were washed 2 times with PBS.
NLC suspensions and positive and negative controls were added to the wells. Positive control was
DMEM. Negative control was Triton X100 2% (m/m).  Lyophilized NLCs were resuspended in
DMEM.  For  each  NLC  formulation,  5  concentrations  were  used  (1 µg  mL-1,  10 µg mL-1,
100 µg mL-1, 1 000 µg  mL-1 10 000 µg mL-1), and for each concentration 5 wells were used. Cell
plates were left to rest for 24 hours, at 37 ºC.
In the third day, MTT was added to the wells and cell plates were left to rest for 4 hours. At the
end of this  period,  medium was removed,  and Dimethyl  sulfoxide (C2H6OS, M = 78.13 g mol-1,
Sigma Aldrich) was added to each well. Cell plates were protected from light and agitated for 5
minutes.  Then  absorptivity  was  measured  using  a  multi-mode  microplate  reader (Synergy HT,
Biotek Instruments).
This three day procedure was repeated two times for each cell line to replicate results.
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4 Results and discussion
4.1 Particle size and Zeta potential
Mean hydrodynamic particle size for all formulations was found to be around 200 nm, as it is pos-
sible to see in tables 6 and 7. PDI was found to be above 0.100 in all formulations. This indicates
that none of the formulations are monodisperse. As stated in section  3.2.1,  prior to size and zeta
measurements, formulations were filtered with a syringe filter with a porus of 800 nm. The object-
ive of this step was to remove any excess lipid and particle agglomerates. However, it does allow
particles of bigger sizes to coexist in the formulation if the method produces them. The conclusions
to be taken from these results are that the method used in this work does not produce monodisperse
NLC formulations without posterior filtering, but the obtained sizes are within the breathable range,
and with potential to reach the pulmonary alveoli.
Table 6: Mean hydrodynamic particle size and zeta potential for 
unloaded formulations
NLC NLC-M
Mean size / nm 174.4 ± 2.4 197.4 ± 1.4
PDI 0.211 ± 0.012 0.120 ± 0.008
Zeta potential / mV – 20.5 ± 0.8 48.7 ± 2.1
Results: mean ± SD (n ≥ 3)
Results for ζ – potential listed in table 6 show that NLC have a pronounced negative charge, while
NLC-M exhibit a high positive charge. These values point to a successful mannosylation of the
NLCs. As described in section 3.1.4, the process of mannosylation involves adding stearyl ammine
to the formulations, so that nanoparticles have amine groups at the surface. These amine groups are
expected  to  link  to  mannose  molecules  through  a  Schiff's  base.  Amine  groups  are  positively
charged,  so ζ  –  potential  was expected to  become positive.  These results  are  also observed in
table 7, with drug loaded NLCs. All mannosylated formulations exhibit positive charges, contrast-
ing with non-mannosylated formulations. This indicates us that the presence of RIF and RFB in the
formulations does not interfere with the mannosylation process.
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Table 7: Mean hydrodynamic particle size and zeta potential for loaded formulations.
NLC-RIF NLC-M-RIF NLC-RFB NLC-M-RFB
Mean size / nm 210.6 ± 1.2 202.0 ± 3.5 179.1 ± 1.6 213.0 ± 1.8
PDI 0.129 ± 0.007 0.190 ± 0.008 0.114 ± 0.015  0.118 ± 0.014
Zeta potential / mV -20.8 ± 0.9 31.9 ± 0.5 -17.9 ± 1.9 37.6 ± 1.0
Results: mean±SD (n ≥ 3)
Surface charge plays an important role in particle stability. The observed absolute values for ζ –
potential are high, both for NLC and NLC-M. This indicates that the formulations are presumably
stable. Stability of two formulations was monitored through time. Size and  ζ – potential was meas-
ured at day 1, day 30, day 90 and day 180. Results up to day 90 are shown in figure 12 to 14. Mean
size and PDI are shown for NLC (figure 1) and NLC-M (figure 2), and they do increase over time.
Figure 12: Mean size and PDI (± SD) of NLC.
         
Figure 13: Mean size and PDI (± SD) of NLC-M.
Figure 14 shows a slight shift of  ζ – potential  torwards neutrality. However,  more dramatic were
the observations at day 180. These show formulations with visible particulates in suspension. DLS
analysis was not possible, as the software was not able to determine a correlation function from the
acquired data. This points to a shelf stability of the formulations inferior to 6 months.
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4.2 Particle morphology
SEM imaging revealed spherical particles for all formulations, with sizes between 100 and 300 nm.
Both these observations validate the results obtained with DLS, and the method of formulation.  As
we can see in figures  15A to  15B,  it can be observed that  both NLC and NLC-M formulations
exhibit similar morphologies, indicating that the method of mannosylation does not have an effect
on particle shape.  However, images for NLC-M do show smaller particles than NLC. A possible
explanation is that such is simply due to the polidispersity. Different regions may exhibit differences
in observed sizes. To test this hypothesis, a greater number of images should be obtained, particles
should be individually counted and measured, and the results should be compared with the results
from DLS.
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Figure 15: SEM images for NLC and NLC-M
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From figures  16A to  16B,  it can observed that loaded NLCs (NLC-RIF and NLC-RFB) also
exhibit spherical  shapes, which indicates that the method of drug loading is also not  resulting in
morphological changes. The variability of sizes seems  to be higher in drug loaded NLCs (this is
more visible in NLC-RIF images) than with empty NLCs, but this was not observed in PDI meas-
ured with DLS. Again, the region of observation plays an important role in  the perception of the
characteristics of each sample, reinforcing the complementary nature of the different methods used
to evaluate particles size and PDI.
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Figure 16: SEM images for NLC-RIF and NLC-RFB
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4.3 Loading efficiency
Figures  17 and  18 show spectrograms for  the absorbance obtained by NLC-RIF and  NLC-RFB,
respectively. For RIF, spectrum showed three interesting local maximums at 255, 334 and 473 nm.
Linear fit of the plot of concentration versus absorbance was obtained, and wavelength for 334 nm
showed greater R² value. For  RFB, spectrogram showed interesting  local maximums at 208, 279
and  319 nm.  Linear  fit  of  the  plot  of  concentration  versus  absorbance  resulted  in  wavelength
208 nm showing greater R² value. 
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Figure 17: Calibration spectrum and linear fit for RIF.
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Table 8: Concentrations of RIF solutions used in dosing calibration.
Solutions
A B C D E F G H
Cm / mg mL ¹⁻ 0.1000 0.0500 0.0278 0.0167 0.0100 0.0050 0.0028 0.0006
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Spectrophotometric results for drug presence in the supernate of formulations showed low absorb-
ances, and calculations yielded  high loading efficiencies for all formulations  (table  10). Manno-
sylated NLCs did not exhibit reduced loading efficiencies, so the technique may be used without it
reducing the capacity of the nanosystem to incorporate these two drugs.
Table 10: Loading efficiency for non coated and coated formulations.
NLC-RIF NLC-M-RIF NLC-RFB NLC-M-RFB
LE / % 84.1 ± 5.0 82.7 ± 3.3 82.4 ± 5.6 89.4 ± 3.4
Drug to lipid ratio: aprox. 1:70. Results: Mean ± SD (n=3)
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Figure 18: Calibration spectrum and linear fit for RFB.
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Table 9: Concentrations of RFB solutions used in dosing calibration.
Solutions
A B C D E F G
Cm / mg mL-1 0.0604 0.0302 0.0151 0.0101 0.0075 0.0042 0.0017
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4.4 Schiff's base detection
Results obtained for  ζ – potential already indicated that mannose coating was  probably  achieved
with success. This was confirmed by the obtained  FTIR peaks. Figure  19 shows a broad peak at
1566 cm-1 in NLC-M, indicating an N=C connection. This confirms the formation of Schiff's base
(– N=CH –) in NLC-M, and its absence in NLC [87].
4.5 Citotoxicity
Half maximum inhibitory concentration (IC50) was determined for all cell lines, from the viability
results of each for NLC, NLC-M, NLC-M-RIF and NLC-M-RFB. Table 11 summarizes these res-
ults. Figures 20, 21 and 22 show the results for RAW, Calu-3 and A549 cell lines, respectively.
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Figure 19: FTIR spectra of NLC and NLC-M.
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IC50 for all formulations and cell lines was above 100 μg mL-1 (Log10(IC50) > 2), but bellow
1 000 μg mL-1. NLC-M constitutes, however, a notorious exception to this observation, exhibiting,
for  all  cell  lines,  an  IC50  bellow  100 μg mL-1 (Log10(IC50)  < 2).  Drug  loaded  formulations,
although mannosylated, did not show this  behaviour.  Indeed, the loaded drugs seem to lower the
toxicity of the cell lines in the presence of mannose, rendering the IC50 to values similar to the
obtained for NLC in the absence of mannose.
Table 11: IC50 results for RAW, CALU-3 and A549 cell lines.
NLC NLC-M NLC-M-RIF NLC-M-RFB
RAW 2.120 ± 0.267 1.276 ± 0.654 2.215 ± 0.231 2.036 ± 0.844
CALU-3 2.706 ± 0.178 1.482 ± 0.772 2.840 ± 0.265 2.378 ± 0.253
A549 2.259 ± 0.095 1.272 ± 0.452 2.552 ± 0.592 2.269 ± 0.592
Results: Log10(IC50) ± SE
Figure 20 shows cell viability (A) and curve fit (B) RAW cell line. IC50 for NLC, NLC-M, NLC-
M-RIF,  and NLC-M-RFB was 131.9 μg mL-1,  18.88 μg mL-1,  164.2 μg mL-1,  and  108.7 μg mL-1,
respectively.  Although only NLC-M exhibit  an IC50 bellow 100 μg mL-1,  individual results  for
RAW cell line show that for NLC formulation, a concentration of 100 resulted in a cell viability
only little above 50%. NLC-M-RFB showed a lower viability than the other formulations with con-
centrations of 1 and 10  μg mL-1.
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Figure 20: MTT results for Raw cell line (Mean ± SD).
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Figure 21 shows cell viability (A) and curve fit (B) for CALU-3 cell line. IC50 for NLC, NLC-
M,  NLC-M-RIF,  and  NLC-M-RFB  was  508.5 μg mL-1,  30.3 μg mL-1,  691.3 μg mL-1,  and
238.9 μg mL- 1,  respectively.  CALU-3 cell  line showed higher cell  viability than both RAW and
A549 cell lines, for all formulations, although it also exhibits a drop in IC50 for the NLC-M formu-
lation.
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Figure 21: MTT results for CALU-3 cell line (Mean ± SD).
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Figure 22: MTT results for A549 cell line (Mean ± SD).
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Figure 22 shows cell viability (A) and curve fit (B) for A549 cell line. IC50 for NLC, NLC-M,
NLC-M-RIF,  and  NLC-M-RFB  was  181.5 μg mL-1,  18.7 μg mL-1,  356.7 μg mL-1,  and
185.7 μg mL- 1, respectively.
Drug loaded NLCs have a drug content of around 1% (w/w) (see section  4.3). Considering
IC50 values for the studied cell lines, it therefore becomes possible, with these formulations, to
achieve maximum  drug  concentrations,  at  the  site  of  delivery, between  1.08 μg mL-1 and
6.91 μg mL-1.
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5 Conclusions and future prospects
With the presented method, it was possible to develop formulations consisting of NLCs coated with
mannose and loaded with RIF and RFB. The size of the produced particles was determined by DLS
and found to be around 200 nm, which should be adequate for lung deposition, based on data found
in the scientific literature. This validates the proposed route of administration, which was the pul-
monary route. With this passive targeting strategy, NLCs of this size are expected to reach the pul-
monary alveoli.  A breathable formulation presents many advantages in the case of TB, since the
MTb exists primarily inside the AMs, in the pulmonary alveoli. A strategy that succeeds in deliver
anti-TB drugs directly to the alveoli may increase treatment efficacy, and, on the other hand, it may
suite the needs of a strategy to overcome patient non-compliance. ζ – potential was considerably
high for all formulations, which suggested a fairly good shelf life stability. Further stability studies
showed that diluted formulations had a shelf life of at least 3 months, but probably no longer than 6
months. Lyophilization of the formulation may be used to solve this issue.
Mannose surface modification was done to  take advantage of sugar  receptors  in  AMs and
improve cellular uptake, an active targeting strategy. The difference in the ζ – potential between the
non mannosylated and the mannosylated NLCs constituted the first evidence that the mannosylation
process was successful. This was later confirmed by FTIR spectrum analysis, which allowed for the
detection of a Schiff's base.
Morphology of the NLCs was studied by SEM imaging. Results showed spherical particles,
with sizes consistent with DLS analysis. The variability in the observed sizes is explained by the
PDI of the formulations. To obtain formulations with lower PDI values, such that they could be con-
sidered monodisperse, filtration could be done with porous of lower diameters, such as 450 nm or
even 200 nm. In industry, other methods to produce NLCs could be used, and some of them, like
high pressure homogenization, will naturally produce monodisperse populations of particles.
Another positive and promising achievement of this  work,  were the results  regarding drug
loading. To optimize the formulation and improve drug loading, several solid lipids were tested, and
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Precirol  ATO  5  was  chosen  for  the  final  formulation.  This  resulted  in  LE  that  ranged  from
82.4 ± 5.7 % to 87.5 ± 4.6 %, for a drug to lipid ratio of approximately 1:70.
Cytotoxicity of the NLCs was studied by MTT assay,  using RAW, CALU-3 and A549 cell
lines.  Results  showed  that  it  was  possible  to  reach  concentrations  above 100  and  below
1 000 μg mL-1  before IC50 was reached, for drug loaded formulations. Other toxicity studies, such
as the lactate dehydrogenase assay, could be used in the future to complement these results. Other
in vitro studies may shed a light on the real possibilities of these nanocarriers. Cellular uptake stud-
ies should be performed to access if the use of NLCs does enhance the uptake of drugs, and if man-
nose coating indeed improves these values.
After all in vitro studies are duly performed, in vivo studies should be considered. These studies
should be planned to answer some pertinent questions. Will the delivery strategy allow for the drug
to reach the circulatory and lymphatic systems, hence be used to fight extra-pulmonary TB? Will
the particles achieve a successful deposition in the pulmonary alveoli? If so, will they truly enhance
cellular uptake of RIF and RFB, reducing side effects and enhancing bioavailability?
These further studies may present this strategy as an important tool to fight TB, but it may find
difficulties which would render it impossible to apply. So far, and despite all the studies considering
the possibility, no breathable formulation for the treatment of TB is available in the market. How-
ever, from these facts it does not follow that the pursuit of an NLC formulation to fight TB should
be dropped. On the contrary, these initial results are very promising, and so they should encourage
us to go farther.
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